Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
Real-time Quote. Real-time Tradegate - 07/17 03:59:22 pm
25.55 EUR   -0.12%
07/16EVOTEC : expands its iPSC discovery platform
AQ
07/15EVOTEC : Expands its ipsc discovery platform
EQ
07/12EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : bags US$23.8m to fight tuberculosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2019 | 06:56am EDT

Evotec SE entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (TB). Current standard therapy for TB consists of a lasts at least six months and combines four drugs administered if the TB pathogen is not drug resistant.

The main objective of the partnership is to generate standardised, high-quality pre-clinical data to support the selection and development of new conbination therapies that are safer, shorter in duration and more efficacious than the current standard of care.

TB is an airborne infectious disease most commonly caused by Mycobacterium tuberculosis. In 2017, 10 million people fell ill with TB, and 1.6 million died from the disease. The disease disproportionally affects young children, with an estimated 1 million children falling ill with TB and 230,000 of them dying in 2017. TB is also a leading cause of death for people living with HIV, with 300,000 of such patients dying in (2017). Multidrug-resistant TB is a health security threat. The WHO estimates that in 2017 there were 558,000 new cases with resistance to rifampicin, the most effective first-line drug, 82% of which were MDR-TB. As a result of years of inadequate diagnosis and treatment, these types of drug-resistant TB are more difficult and costly to treat, highlighting the urgent need for new, better, faster-acting treatments.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC SE
07/16EVOTEC : expands its iPSC discovery platform
AQ
07/15EVOTEC : Expands its ipsc discovery platform
EQ
07/12EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
07/08Eurofins to slow pace of M&A, expand in emerging markets
RE
07/08EVOTEC : and venture capital consortium form 'Breakpoint Therapeutics GmbH'
AQ
07/08EVOTEC : And venture capital consortium form 'breakpoint therapeutics gmbh'
EQ
07/04EVOTEC : completes acquisition of Just Biotherapeutics
AQ
07/03EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
07/03EVOTEC : Completes acquisition of just biotherapeutics
EQ
06/28EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
More news
Financials (EUR)
Sales 2019 417 M
EBIT 2019 76,6 M
Net income 2019 55,3 M
Finance 2019 64,1 M
Yield 2019 -
P/E ratio 2019 64,1x
P/E ratio 2020 64,4x
EV / Sales2019 9,03x
EV / Sales2020 8,11x
Capitalization 3 828 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 26,20  €
Last Close Price 25,56  €
Spread / Highest target 29,1%
Spread / Average Target 2,50%
Spread / Lowest Target -21,8%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE47.31%4 217
IQVIA HOLDINGS INC34.78%31 409
LONZA GROUP32.31%25 111
CELLTRION, INC.--.--%20 827
INCYTE CORPORATION25.62%17 419
EXACT SCIENCES CORPORATION82.17%15 001